Knowledge of the molecular biology of CML has provided the development of tyrosine kinase inhibitors (TKIs), able to directly target Bcr‐Abl, and inhibit its downstream activity, offering patients in CP the possibility of achieving remission and prolong survival. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.